Amarin (NASDAQ:AMRN) Now Covered by Analysts at StockNews.com

StockNews.com started coverage on shares of Amarin (NASDAQ:AMRN) in a report issued on Monday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Amarin Stock Down 2.3 %

Amarin stock opened at $0.43 on Monday. The firm has a fifty day moving average of $0.52 and a 200-day moving average of $0.54. Amarin has a 52-week low of $0.35 and a 52-week high of $1.11. The firm has a market capitalization of $177.41 million, a P/E ratio of -4.80 and a beta of 1.82.

Amarin shares are going to reverse split on Friday, April 11th. The 1-20 reverse split was announced on Wednesday, March 12th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, April 10th.

Amarin (NASDAQ:AMRN) last issued its quarterly earnings data on Wednesday, March 12th. The biopharmaceutical company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Amarin had a negative return on equity of 7.22% and a negative net margin of 16.33%. The company had revenue of $62.31 million for the quarter, compared to analyst estimates of $32.37 million. On average, research analysts expect that Amarin will post -0.15 EPS for the current fiscal year.

Institutional Trading of Amarin

Large investors have recently bought and sold shares of the company. Arkfeld Wealth Strategies L.L.C. lifted its position in shares of Amarin by 52.6% during the fourth quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company’s stock worth $30,000 after purchasing an additional 20,000 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS purchased a new stake in Amarin during the 4th quarter worth $36,000. Generation Capital Management LLC acquired a new position in Amarin in the 4th quarter worth $50,000. Stonepine Capital Management LLC purchased a new position in Amarin in the 4th quarter valued at about $55,000. Finally, New York State Common Retirement Fund acquired a new stake in shares of Amarin during the fourth quarter valued at about $68,000. Institutional investors and hedge funds own 22.25% of the company’s stock.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.